Our webinars have true cross-functional value for everyone working in market access in the pharmaceutical industry. From non-expert audiences through to subject-matter experts. You can sign up for our free webinar program, or contact us to discuss tailoring a webinar to your audience.
EUnetHTA Joint Clinical Assessments: where have we come from and where are we going?
Future proofing for the 2020s market access trends
Managed entry agreements lessons from EU5
CAR-T therapy the future begins to take shape
Indication specific pricing the obvious solution
Payer perspectives on cell and gene therapies: opportunities and challenges
Market access considerations for CAR-Ts: insights from ASH
Patient-centricity: shaping value generation for HTA and market access
Market access update key learnings from ASCO and EHA 2017
Market access for PD-1 inhibitors: where are we now?
Hemato-oncology market access update: key learnings from ASH
Keeping ahead of the curve: using HTA learnings to drive market access strategy
The new CDF: opportunities and challenges
Market access update: key learnings from EHA and ASCO
PRMA HealthCheck™: benchmarking your evidence against payer requirements
Does 1+1 always equal 2? Valuing combinations
Clarity or confusion: the role of value frameworks in oncology
Health technology assessment and market access learnings from the experience of PD-1 inhibitors
Unlocking the market access potential of immuno-oncology agents
Emerging trends in oncology market access: issues that should be on your radar
Subgroups and market access: developing informed strategy
Thinking strategically about subgroups and ITC
Launching on Phase 2 single-arm data? Real-world evidence strategies to support HTA